Invention Grant
- Patent Title: Tumor vaccination involving a humoral immune response against self-proteins
-
Application No.: US14457897Application Date: 2014-08-12
-
Publication No.: US09617321B2Publication Date: 2017-04-11
- Inventor: Thorsten Klamp , Ugur Sahin , Ozlem Tureci , Michael Koslowski , Thomas Hiller , Jens Schumacher
- Applicant: BioNTech AG
- Applicant Address: DE Mainz DE Mainz
- Assignee: JOHANNES GUTENBERG-UNIVERSITAT MAINZ,BIONTECH AG
- Current Assignee: JOHANNES GUTENBERG-UNIVERSITAT MAINZ,BIONTECH AG
- Current Assignee Address: DE Mainz DE Mainz
- Agency: McAndrews, Held & Malloy, Ltd.
- Priority: EP10002775 20100316; EP10016216 20101230
- Main IPC: A61K39/00
- IPC: A61K39/00 ; C07K14/47 ; C07K14/005 ; C12N7/00

Abstract:
The present invention relates to tumor immunotherapy, in particular to tumor vaccination, using chimeric proteins comprising all or a portion of a hepatitis B virus core antigen protein and an amino acid sequence comprising an epitope derived from the extracellular portion of a tumor-associated antigen. In particular, the present invention provides virus-like particles comprising said chimeric proteins, which are useful for eliciting a humoral immune response in a subject against the tumor-associated antigen, in particular against cells carrying said tumor-associated antigen on their surface, wherein the tumor-associated antigen is a self-protein in said subject.
Public/Granted literature
- US20150152154A1 TUMOR VACCINATION INVOLVING A HUMORAL IMMUNE RESPONSE AGAINST SELF-PROTEINS Public/Granted day:2015-06-04
Information query